Particularly, in de-differentiated liposarcomas, which share similarities with the aggressiveness of pancreatic cancer, MDM2 inhibitors have shown efficacy, hinting at their potential applicability in advancing also the treatment landscape for pancreatic malignancies [60]. The gene discussed is MDM2; the disease is pancreatic neoplasm.